The New Reality of Oncology Trials: Designing RTSM for Change, Not Just Day One

In clinical research, complexity is rarely static. Especially in oncology, study designs evolve as new data emerges, enrollment progresses, and sponsors make decisions about cohorts, treatment arms, dosing strategies, and geographic expansion. For CROs responsible for helping sponsors execute these studies, that creates an important question: Is the technology supporting the trial designed for the study as it exists today, or for how it may need to operate tomorrow? Increasingly, that distinction matters.

Complexity doesn’t end at study build

An RTSM system may be designed around a protocol at a specific point in time, but the study itself continues to evolve. A sponsor may need to open a new cohort… The question quickly becomes not only what needs to change, but how quickly and safely can we implement that change without introducing unnecessary disruption? That is where the architecture of the RTSM becomes increasingly important.

Designing for change instead of designing around it

Historically, flexibility in clinical technology has often meant customization. A more modern approach is to make adaptability part of the platform itself. Endpoint Clinical’s Elosity® was designed around that idea. Its configuration-first architecture gives study teams greater flexibility to accommodate evolving requirements without treating every change as a custom development exercise. Version control, comprehensive audit trails, and human-readable audit history provide complete visibility into what changed, when it changed, who initiated the change, and how it was deployed. This level of traceability helps study teams maintain control as the system evolves and supports inspection readiness by providing documented evidence of change management activities throughout the study lifecycle.

Adaptability with Regulatory Oversight Built In

In highly adaptive clinical trials, the ability to implement change is only part of the equation. Equally important is the ability to demonstrate precisely how those changes were evaluated, approved, configured, tested, and deployed within a regulated environment. Endpoint Clinical’s Elosity platform was designed with this reality in mind. The platform’s comprehensive audit trail capabilities automatically capture system changes throughout the study lifecycle, providing a detailed record of configuration modifications, version updates, user actions, approvals, and deployment activities. For CROs and sponsors preparing for inspections, the platform not only supports adaptation throughout the course of the study, but also helps provide the evidence needed to demonstrate that those adaptations were managed in a controlled, compliant, and fully auditable manner.

Oncology makes adaptability particularly important

Consider an oncology study that begins with several treatment arms and later needs to introduce an additional cohort based on emerging data. Technology that is designed to accommodate controlled change can help CRO and sponsor teams evaluate modifications, implement them efficiently, and maintain a clear record of how the system has evolved..

What CROs should be asking of RTSM technology

For CROs, selecting technology for a complex study should involve more than determining whether a system can support the protocol presented at kickoff. What happens when the protocol changes? Can those changes be implemented while maintaining quality, traceability, and oversight expected in a regulated environment?

Building for the study you haven’t seen yet

The goal should not be to predict every change. It should be to build a technology foundation capable of responding when change happens while maintaining the traceability, governance, and regulatory oversight required in modern clinical research. The ability to prove changes were managed in a controlled, compliant, and fully auditable manner may be equally valuable.